Bicycle Therapeutics (BCYC) Projected to Post Quarterly Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 2:00 AM ET.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $5.24 on Tuesday. The company has a market capitalization of $363.50 million, a PE ratio of -1.45 and a beta of 1.63. The company’s 50 day moving average price is $6.60 and its 200 day moving average price is $7.10. Bicycle Therapeutics has a 52 week low of $5.18 and a 52 week high of $13.11.

Insider Activity at Bicycle Therapeutics

In related news, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,029 shares of company stock valued at $251,966. Corporate insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group bought a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $69,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter worth $70,000. Vontobel Holding Ltd. bought a new position in Bicycle Therapeutics during the fourth quarter worth $71,000. Sei Investments Co. acquired a new position in Bicycle Therapeutics during the 2nd quarter valued at $74,000. Finally, Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BCYC shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 price target for the company. Citigroup reissued an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.20.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.